Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Children with HIV in Africa second-line antiretroviral regimen trial
ISRCTN22964075Phase 3Completed
- Sponsor
- University College London
- Start
- Dec 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, atazanavir, ritonavir, darunavir, lopinavir and 5 more in human immunodeficiency virus infection (HIV) (8 arms), sponsored by University College London. Primary endpoint: Primary virologic response. Started Dec 2018; status: completed.
02
Drugs
dolutegraviratazanavirritonavirdarunavirlopinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN22964075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN22964075.